PMAIP1 and hematopoietic and lymphoid cell neoplasm: As low NOXA expression has been demonstrated to mediate venetoclax resistance in hematologic cancers [25,34], we hypothesized that low NOXA expression could also explain SS resistance to venetoclax (VTX) (Figure 1D).